

Environmental Risk Assessment

Environmental risk for non-GMOs (Genetically modified organisms) containing medicinal products

The proposed product Remdesivir for injection 100 mg/vial for marketing are generically-equivalent product that will be prescribed interchangeably with, and instead of, other products containing remdesivir already in the market. The introduction of this product onto the market is unlikely to result in any significant increase in the combined total sales volumes for all the pharmaceutical products containing remdesivir and thus would not be expected to have an adverse effect upon the environment *per se*.

For this reason, a formal environmental risk assessment is not considered to be necessary.

Mohan
Daburkar

Digitally signed by Mohan Daburkar
DN: cn=Mohan Daburkar, o=Cipla Ltd. Vikhroli, ou=IPD, email=Mohan.Daburkar@cipla.com, c=IN
Date: 2020.09.03 10:30:11 +05'30'

Mr Mohan Daburkar
Cipla Ltd., India

